Drug intelligence / Profile preview

Autologous CD34+ and CD133+ Stem Cells

Development stage: Phase 2
Lead developer: Stem Cells Arabia
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

Autologous CD34+ and CD133+ Stem Cells is an investigational cell therapy developed by Stem Cells Arabia for the treatment of chronic complete spinal cord injury (SCI). The therapy involves the isolation and purification of autologous hematopoietic stem cells (HSCs) expressing the CD34 and CD133 markers, which are harvested from the patient's own bone marrow or peripheral blood via leukapheresis. These unmanipulated, purified stem cells are then transplanted directly into the site of the spinal cord injury. The treatment is designed to promote neural repair and functional recovery through potential mechanisms such as paracrine signaling, immunomodulation, or cellular differentiation. Clinical evaluation, including a Phase I/II trial (NCT02687672), focuses on assessing safety and improvements in sensory and motor functions using the American Spinal Injury Association (ASIA) impairment scale in both pediatric and adult populations.

Other names: Stem Cell Transplantation-Stem Cells Arabia-spinal cord injuryPurified Autologous Bone Marrow- or Leukapheresis-Derived CD34+ and CD133+Autologous CD34+ and CD133+ Stem Cell Transplantation

Beyond the preview

Go deeper on Autologous CD34+ and CD133+ Stem Cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autologous CD34+ and CD133+ Stem Cells.

Explore the full profile